<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7256451\results\search\disease\results.xml">
  <result pre="*Correspondence: Eugenie R. Lumbers eugenie.lumbers@newcastle.edu.au This article was submitted to" exact="Pulmonary" post="Medicine, a section of the journal Frontiers in Medicine"/>
  <result pre="is the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung" exact="and heart" post="from acute respiratory distress syndrome (ARDS) and acute myocarditis"/>
  <result pre="the receptor for COVID-19 (SARs-CoV-2). ACE2 protects the lung and" exact="heart" post="from acute respiratory distress syndrome (ARDS) and acute myocarditis"/>
  <result pre="for COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from" exact="acute" post="respiratory distress syndrome (ARDS) and acute myocarditis and arrhythmias,"/>
  <result pre="COVID-19 (SARs-CoV-2). ACE2 protects the lung and heart from acute" exact="respiratory" post="distress syndrome (ARDS) and acute myocarditis and arrhythmias, because"/>
  <result pre="ACE2 protects the lung and heart from acute respiratory distress" exact="syndrome" post="(ARDS) and acute myocarditis and arrhythmias, because it breaks"/>
  <result pre="lung and heart from acute respiratory distress syndrome (ARDS) and" exact="acute" post="myocarditis and arrhythmias, because it breaks down Angiotensin II,"/>
  <result pre="and heart from acute respiratory distress syndrome (ARDS) and acute" exact="myocarditis" post="and arrhythmias, because it breaks down Angiotensin II, which"/>
  <result pre="down Angiotensin II, which has inflammatory effects in the lung" exact="and heart" post="as well as in the kidney. When SARS-CoV-2 binds"/>
  <result pre="Angiotensin II, which has inflammatory effects in the lung and" exact="heart" post="as well as in the kidney. When SARS-CoV-2 binds"/>
  <result pre="lost. Death from COVID-19 is due to ARDS and also" exact="heart" post="failure and acute cardiac injury. Drugs that prevent the"/>
  <result pre="COVID-19 is due to ARDS and also heart failure and" exact="acute" post="cardiac injury. Drugs that prevent the inflammatory actions of"/>
  <result pre="actions of Angiotensin II (i.e., Angiotensin receptor blockers, ARBs) prevent" exact="acute" post="lung injury caused by SARS-CoV. Clinical trials are underway"/>
  <result pre="treatments are also discussed. renin-angiotensin system (RAS) ACE2 lung injury" exact="cardiovascular disease" post="COVID-19 SARS- CoV-2 fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
  <result pre="are also discussed. renin-angiotensin system (RAS) ACE2 lung injury cardiovascular" exact="disease" post="COVID-19 SARS- CoV-2 fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
  <result pre="explains how the renin-angiotensin system (RAS) interacts with the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and also with the novel"/>
  <result pre="how the renin-angiotensin system (RAS) interacts with the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and also with the novel coronavirus,"/>
  <result pre="the renin-angiotensin system (RAS) interacts with the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and also with the novel coronavirus, SARS-CoV-2,"/>
  <result pre="(SARS-CoV) and also with the novel coronavirus, SARS-CoV-2, which causes" exact="infection" post="and subsequent acute lung and probably heart injury [COVID-19"/>
  <result pre="with the novel coronavirus, SARS-CoV-2, which causes infection and subsequent" exact="acute" post="lung and probably heart injury [COVID-19 (1â€&quot;3)]. As well"/>
  <result pre="SARS-CoV-2, which causes infection and subsequent acute lung and probably" exact="heart" post="injury [COVID-19 (1â€&quot;3)]. As well as identifying potential therapeutic"/>
  <result pre="(1â€&quot;3)]. As well as identifying potential therapeutic strategies for treating" exact="acute" post="lung injury and myocarditis in COVID-19 [see also (4â€&quot;6)],"/>
  <result pre="identifying potential therapeutic strategies for treating acute lung injury and" exact="myocarditis" post="in COVID-19 [see also (4â€&quot;6)], this article provides a"/>
  <result pre="article provides a background to the management of patients with" exact="essential hypertension" post="in accordance with recommendations made in the joint statement"/>
  <result pre="provides a background to the management of patients with essential" exact="hypertension" post="in accordance with recommendations made in the joint statement"/>
  <result pre="with recommendations made in the joint statement issued by the" exact="Heart Failure" post="Society of America, the American College of Cardiology and"/>
  <result pre="recommendations made in the joint statement issued by the Heart" exact="Failure" post="Society of America, the American College of Cardiology and"/>
  <result pre="statement issued by the Heart Failure Society of America, the" exact="American" post="College of Cardiology and the American Heart Association (7)"/>
  <result pre="Society of America, the American College of Cardiology and the" exact="American" post="Heart Association (7) that patients who are using drugs"/>
  <result pre="of America, the American College of Cardiology and the American" exact="Heart" post="Association (7) that patients who are using drugs that"/>
  <result pre="angiotensin receptor blockers (ARBs) is associated with less severe COVID-19" exact="infections" post="(8, 9). There are two major arms of the"/>
  <result pre="the RAS, one arm, the Angiotensin II (Ang II)-Ang II" exact="type 1" post="receptor (AT1R) pathway is pro-inflammatory and can cause acute"/>
  <result pre="type 1 receptor (AT1R) pathway is pro-inflammatory and can cause" exact="acute" post="lung injury (10, 11). The other arm, the angiotensin-converting"/>
  <result pre="Note the effects of Angiotensin II via the Angiotensin II" exact="type I" post="receptor (AT1R) are blocked by its interaction with the"/>
  <result pre="(AT1R) are blocked by its interaction with the Angiotensin II" exact="type II" post="receptor (AT2R) and by its metabolism to Angâ€&quot;(1-7) acting"/>
  <result pre="the ACE2-Angâ€&quot;(1-7)-MasR pathway and it is this imbalance that causes" exact="acute" post="lung injury (13). A multi-centered double blind clinical trial"/>
  <result pre="imbalance that causes acute lung injury (13). A multi-centered double" exact="blind" post="clinical trial has recently been established to test the"/>
  <result pre="of viruses that have in recent years caused epidemics of" exact="acute" post="respiratory syndromes. The first major epidemic was SARS (Severe"/>
  <result pre="viruses that have in recent years caused epidemics of acute" exact="respiratory" post="syndromes. The first major epidemic was SARS (Severe Acute"/>
  <result pre="acute respiratory syndromes. The first major epidemic was SARS (Severe" exact="Acute" post="Respiratory Syndrome)-CoV in 2003 which was responsible for 8,000"/>
  <result pre="respiratory syndromes. The first major epidemic was SARS (Severe Acute" exact="Respiratory" post="Syndrome)-CoV in 2003 which was responsible for 8,000 deaths;"/>
  <result pre="responsible for 8,000 deaths; the second was MERS (Middle East" exact="Respiratory" post="Syndrome), which occurred in 2012. The most recent is"/>
  <result pre="the world. SARS-CoV-2 is already responsible for more cases of" exact="infection" post="and also more deaths than the two previous coronavirus"/>
  <result pre="There are also a number of other coronaviruses that cause" exact="upper" post="respiratory tract infections, in particular HCoV-NL63. SARS-CoV and SARS-CoV-2"/>
  <result pre="are also a number of other coronaviruses that cause upper" exact="respiratory" post="tract infections, in particular HCoV-NL63. SARS-CoV and SARS-CoV-2 both"/>
  <result pre="as does HCoV-NL63 (15). HCoV-NL63, like SARS-CoV-2, can cause mild" exact="respiratory" post="infections, but most commonly affects the young (16). It"/>
  <result pre="affects the young (16). It has, however, been associated with" exact="bronchiolitis" post="and croup but does not cause the acute respiratory"/>
  <result pre="young (16). It has, however, been associated with bronchiolitis and" exact="croup" post="but does not cause the acute respiratory distress syndrome"/>
  <result pre="associated with bronchiolitis and croup but does not cause the" exact="acute" post="respiratory distress syndrome (ARDS) characteristic of SARS-CoV-2 infection. The"/>
  <result pre="with bronchiolitis and croup but does not cause the acute" exact="respiratory" post="distress syndrome (ARDS) characteristic of SARS-CoV-2 infection. The differences"/>
  <result pre="and croup but does not cause the acute respiratory distress" exact="syndrome" post="(ARDS) characteristic of SARS-CoV-2 infection. The differences in the"/>
  <result pre="al. in a clinical study of 140 patients found that" exact="hypertension" post="and diabetes were the two most common comorbidities in"/>
  <result pre="a clinical study of 140 patients found that hypertension and" exact="diabetes" post="were the two most common comorbidities in patients with"/>
  <result pre="the prevalence of these two comorbidities in patients with severe" exact="disease" post="was not significant when compared with those with infections"/>
  <result pre="severe disease was not significant when compared with those with" exact="infections" post="that were not severe (23). In a study by"/>
  <result pre="patients reached the composite end-point. It should be noted that" exact="hypertension" post="and diabetes are very common comorbidities, no other co-existing"/>
  <result pre="the composite end-point. It should be noted that hypertension and" exact="diabetes" post="are very common comorbidities, no other co-existing disorders were"/>
  <result pre="This debate has not adequately considered the roles of local" exact="pulmonary" post="and circulating RASs in the pathogenesis of COVID-19. Put"/>
  <result pre="SARS-CoV and SARS-CoV-2, also activates a RAS pathway that prevents" exact="acute" post="lung injury (1, 2). These â€˜Ying' and â€˜Yang' actions"/>
  <result pre="the use of RAS blocking drugs in the treatment of" exact="hypertension" post="and diabetes. This is because while they upregulate the"/>
  <result pre="while they upregulate the SARS-CoV-2 receptor (ACE2) (a means for" exact="viral" post="entry into cells), they also protect tissues from the"/>
  <result pre="the RAS that are involved in the pathogenesis of coronavirus-induced" exact="acute" post="lung injury. We have avoided including a number of"/>
  <result pre="hypertension; it raises blood pressure both through actions in the" exact="brain" post="on the sympathetic nervous system, and in peripheral blood"/>
  <result pre="in the brain on the sympathetic nervous system, and in" exact="peripheral" post="blood vessels causing vasoconstriction. This axis also controls sodium"/>
  <result pre="the brain on the sympathetic nervous system, and in peripheral" exact="blood vessels" post="causing vasoconstriction. This axis also controls sodium reabsorption partly"/>
  <result pre="is an endocrine system capable of reaching the brain, the" exact="heart" post="and the lungs but there are also local tissue"/>
  <result pre="in many organs, such as the heart, the kidney, the" exact="female" post="reproductive tract, and the brain. There is also a"/>
  <result pre="RAS (27) that has been implicated in the etiology of" exact="pulmonary" post="fibrosis (11, 28). Through a combination of circulating and"/>
  <result pre="liver. Ang I in the venous blood returning to the" exact="heart" post="and lungs is converted in the lung by ACE"/>
  <result pre="of ACE2 throughout the body (33), including the lungs (11)," exact="heart" post="(34, 35), and kidney (36). Coronaviruses gain access to"/>
  <result pre="kidney (36). Coronaviruses gain access to the body via the" exact="respiratory" post="tract and it has recently been shown that nasal"/>
  <result pre="and it has recently been shown that nasal goblet cells," exact="type II" post="pneumocytes and ileal enterocytes all possess the necessary combination"/>
  <result pre="all possess the necessary combination of ACE2 and TMPRSS2 for" exact="viral" post="entry to be successful (31, 37). HCoV-NL63 binds to"/>
  <result pre="to be successful (31, 37). HCoV-NL63 binds to human airway" exact="epithelial" post="cells in vitro (38). In the lung, ACE2 is"/>
  <result pre="the lung, ACE2 is widely distributed throughout the bronchial and" exact="pulmonary" post="epithelium and the pulmonary capillaries (39). ACE2 protects the"/>
  <result pre="widely distributed throughout the bronchial and pulmonary epithelium and the" exact="pulmonary" post="capillaries (39). ACE2 protects the lung from the pro-inflammatory"/>
  <result pre="young people are more likely to get the SARS coronavirus" exact="infection" post="than older people, as appears to be the case."/>
  <result pre="be species specific differences. In the lungs (1, 2), the" exact="heart" post="(35, 41), and the kidney, ACE2 (36) protects against"/>
  <result pre="also sustained. As well, it has been shown in the" exact="heart" post="that ARBs cause upregulation of ACE2 because they prevent"/>
  <result pre="did not get infected with SARS-CoV and did not get" exact="acute" post="lung inflammation (13). Thus, it would appear that low"/>
  <result pre="not get infected with SARS-CoV and did not get acute" exact="lung inflammation" post="(13). Thus, it would appear that low levels of"/>
  <result pre="inflammation (13). Thus, it would appear that low levels of" exact="pulmonary" post="ACE2 protect against coronavirus infection. There is however a"/>
  <result pre="is however a sinister side effect to the loss of" exact="pulmonary" post="ACE2 because it plays a critical role in preventing"/>
  <result pre="pulmonary ACE2 because it plays a critical role in preventing" exact="acute" post="lung injury. Xie et al. suggest that there is"/>
  <result pre="if young people, like other mammals, have high levels of" exact="pulmonary" post="ACE2, they should be more susceptible to symptomatic infection"/>
  <result pre="levels of pulmonary ACE2, they should be more susceptible to" exact="symptomatic" post="infection with coronaviruses. The prevalence of infection is however"/>
  <result pre="of pulmonary ACE2, they should be more susceptible to symptomatic" exact="infection" post="with coronaviruses. The prevalence of infection is however based"/>
  <result pre="more susceptible to symptomatic infection with coronaviruses. The prevalence of" exact="infection" post="is however based on the appearance of symptoms and"/>
  <result pre="on the appearance of symptoms and in the young, the" exact="disease" post="is usually so mild that infection rates appear to"/>
  <result pre="in the young, the disease is usually so mild that" exact="infection" post="rates appear to be low. In fact, the milder"/>
  <result pre="to be low. In fact, the milder nature of the" exact="disease" post="in the young compared to the old could be"/>
  <result pre="studies and human data may well be related to the" exact="short" post="life span of animals used and the fact that"/>
  <result pre="that they are housed in environments that protect them from" exact="infections" post="and pollution etc. It has also been claimed that"/>
  <result pre="there is no evidence that ARBs have this effect on" exact="pulmonary" post="ACE2, but ARBs upregulate cardiac ACE2. Ang II levels"/>
  <result pre="and fibroblasts (42). Therefore, the overall effects of ARBs on" exact="pulmonary" post="ACE2 could be modified by counteracting the effects of"/>
  <result pre="ACE2 could be modified by counteracting the effects of Angâ€&quot;(1-7)." exact="Hypertension" post="and diabetes are the most common comorbidities found in"/>
  <result pre="be modified by counteracting the effects of Angâ€&quot;(1-7). Hypertension and" exact="diabetes" post="are the most common comorbidities found in patients suffering"/>
  <result pre="a study comparing 113 patients who died with COVID-19 infections," exact="hypertension" post="and cardiovascular disease were more common than in patients"/>
  <result pre="comparing 113 patients who died with COVID-19 infections, hypertension and" exact="cardiovascular disease" post="were more common than in patients who recovered (161)."/>
  <result pre="113 patients who died with COVID-19 infections, hypertension and cardiovascular" exact="disease" post="were more common than in patients who recovered (161)."/>
  <result pre="were more common than in patients who recovered (161). Furthermore," exact="acute" post="cardiac injury and heart failure, like acute respiratory distress"/>
  <result pre="than in patients who recovered (161). Furthermore, acute cardiac injury" exact="and heart" post="failure, like acute respiratory distress syndrome and respiratory failure,"/>
  <result pre="in patients who recovered (161). Furthermore, acute cardiac injury and" exact="heart" post="failure, like acute respiratory distress syndrome and respiratory failure,"/>
  <result pre="recovered (161). Furthermore, acute cardiac injury and heart failure, like" exact="acute" post="respiratory distress syndrome and respiratory failure, contributed to the"/>
  <result pre="(161). Furthermore, acute cardiac injury and heart failure, like acute" exact="respiratory" post="distress syndrome and respiratory failure, contributed to the critical"/>
  <result pre="acute cardiac injury and heart failure, like acute respiratory distress" exact="syndrome" post="and respiratory failure, contributed to the critical nature of"/>
  <result pre="injury and heart failure, like acute respiratory distress syndrome and" exact="respiratory" post="failure, contributed to the critical nature of the illness"/>
  <result pre="(46). The Role of ACE2 In Protecting The Lung and" exact="Heart" post="From ANG II Induced Inflammation ACE2 protects the lung"/>
  <result pre="From ANG II Induced Inflammation ACE2 protects the lung from" exact="acute" post="lung injury because it reduces levels of Ang II"/>
  <result pre="role in the prevention of lung injury. Briefly, they induced" exact="acute" post="lung injury in mice by sepsis, lipopolysaccharide (LPS) endotoxin"/>
  <result pre="endotoxin or by acid aspiration. These treatments all caused severe" exact="lung inflammation" post="in ACE2-/- knockout mice, which was mitigated by intraperitoneal"/>
  <result pre="of ACE2 from the lung caused by the binding of" exact="viral" post="spike protein was responsible for the acute lung injury"/>
  <result pre="the binding of viral spike protein was responsible for the" exact="acute" post="lung injury caused by coronavirus infections. They also showed,"/>
  <result pre="be expected from the known actions of ACE2, that this" exact="viral infection" post="was associated with raised Ang II levels, which caused"/>
  <result pre="expected from the known actions of ACE2, that this viral" exact="infection" post="was associated with raised Ang II levels, which caused"/>
  <result pre="infection was associated with raised Ang II levels, which caused" exact="acute" post="lung injury via the Ang II-AT1R pathway. Treatment with"/>
  <result pre="ARB, losartan, prevented SARS-CoV-induced lung injury (13). We suggest that" exact="pulmonary" post="ACE2 plays a critical role in protecting the lung"/>
  <result pre="II-AT1R induced inflammation because not only is there a local" exact="pulmonary" post="RAS but the lung is also the major site"/>
  <result pre="of ACE2, by binding of SARS-CoV-2, not only exposes the" exact="pulmonary" post="epithelium to locally formed Ang II but also to"/>
  <result pre="circulating Ang I. Recently, a SARS-CoV-2 infected patient presented with" exact="acute" post="heart failure a week after experiencing â€œflu-like symptomsâ€� and"/>
  <result pre="Ang I. Recently, a SARS-CoV-2 infected patient presented with acute" exact="heart" post="failure a week after experiencing â€œflu-like symptomsâ€� and was"/>
  <result pre="a week after experiencing â€œflu-like symptomsâ€� and was diagnosed with" exact="acute" post="myocarditis without any interstitial pneumonitis (48). It is known"/>
  <result pre="week after experiencing â€œflu-like symptomsâ€� and was diagnosed with acute" exact="myocarditis" post="without any interstitial pneumonitis (48). It is known that"/>
  <result pre="â€œflu-like symptomsâ€� and was diagnosed with acute myocarditis without any" exact="interstitial pneumonitis" post="(48). It is known that SARS binds to myocardial"/>
  <result pre="ACE2 protein (3). The protective effects of ACE2 in the" exact="heart" post="are well-described (41, 49) and it is the major"/>
  <result pre="major metabolic pathway for breakdown of Ang II in the" exact="heart" post="(50). ACE2 protects the heart from Ang II-AT1R signaling"/>
  <result pre="of Ang II in the heart (50). ACE2 protects the" exact="heart" post="from Ang II-AT1R signaling induced injury (34). Therapeutic Modalities"/>
  <result pre="treating coronavirus infections. While it is most advisable to prevent" exact="viral infection" post="and reduce the viral load, prevention of coronavirus-associated lung"/>
  <result pre="coronavirus infections. While it is most advisable to prevent viral" exact="infection" post="and reduce the viral load, prevention of coronavirus-associated lung"/>
  <result pre="is most advisable to prevent viral infection and reduce the" exact="viral" post="load, prevention of coronavirus-associated lung and cardiac injury saves"/>
  <result pre="ACE2 as a receptor for the virus in the lungs" exact="and heart" post="but a â€œprotectorâ€� of the lungs and heart from"/>
  <result pre="as a receptor for the virus in the lungs and" exact="heart" post="but a â€œprotectorâ€� of the lungs and heart from"/>
  <result pre="the lungs and heart but a â€œprotectorâ€� of the lungs" exact="and heart" post="from coronavirus-induced injury has led to debate concerning the"/>
  <result pre="lungs and heart but a â€œprotectorâ€� of the lungs and" exact="heart" post="from coronavirus-induced injury has led to debate concerning the"/>
  <result pre="in the lung, increase receptor availability and therefore may increase" exact="viral" post="load. There is no doubt, however, that Ang II-acting"/>
  <result pre="no doubt, however, that Ang II-acting via the AT1R causes" exact="acute" post="lung injury and probably cardiac injury when the ACE2-Angâ€&quot;(1-7)-Mas"/>
  <result pre="of ACE2. This pathway also protects from other forms of" exact="acute" post="lung injury as well as SARS-CoV induced injury. ARBs"/>
  <result pre="induced injury. ARBs would prevent downregulation of this pathway once" exact="infection" post="has occurred and ameliorate any unopposed pro-inflammatory effects of"/>
  <result pre="would prevent Ang II-induced inhibition of ACE2 activity. Preventing Coronavirus" exact="Infections" post="In The Lung Since there is an approved serine"/>
  <result pre="the airways with recombinant ACE2 or soluble ACE2 so that" exact="viral" post="particles are â€œmopped upâ€� leaving bronchial pulmonary ACE2 intact."/>
  <result pre="ACE2 so that viral particles are â€œmopped upâ€� leaving bronchial" exact="pulmonary" post="ACE2 intact. Treatment with recombinant human ACE2 could have"/>
  <result pre="use of RAS blocking drugs in the treatment of this" exact="infection" post="(8, 9). Other alternatives, as suggested by Imai et"/>
  <result pre="the efficacy of ARBs and ACEIs in the treatment of" exact="acute" post="lung injury induced by SARS-CoV-2 is welcome news because"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="References References 1.ImaiYKubaKRaoSHuanYGuoFGuanBet al.. Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failure. Nature. (2005) 436:112â€&quot;6. 10.1038/nature0371216001071 2.JiaH. Pulmonary angiotensin-converting"/>
  <result pre="from severe acute lung failure. Nature. (2005) 436:112â€&quot;6. 10.1038/nature0371216001071 2.JiaH." exact="Pulmonary" post="angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock."/>
  <result pre="436:112â€&quot;6. 10.1038/nature0371216001071 2.JiaH. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory" exact="lung disease." post="Shock. (2016) 46:239â€&quot;48. 10.1097/SHK.000000000000063327082314 3.OuditGYKassiriZJiangCLiuPPPoutanenSMPenningerJMet al.. SARS-coronavirus modulation of"/>
  <result pre="Infect Dis. (2020) ciaa329. 10.1093/cid/ciaa329. [Epub ahead of print].32215613 7.collab:" exact="American" post="Heart AssociationThe Heart Failure Society of America The American"/>
  <result pre="Dis. (2020) ciaa329. 10.1093/cid/ciaa329. [Epub ahead of print].32215613 7.collab: American" exact="Heart" post="AssociationThe Heart Failure Society of America The American College"/>
  <result pre="ciaa329. 10.1093/cid/ciaa329. [Epub ahead of print].32215613 7.collab: American Heart AssociationThe" exact="Heart Failure" post="Society of America The American College of Cardiology. Patients"/>
  <result pre="10.1093/cid/ciaa329. [Epub ahead of print].32215613 7.collab: American Heart AssociationThe Heart" exact="Failure" post="Society of America The American College of Cardiology. Patients"/>
  <result pre="7.collab: American Heart AssociationThe Heart Failure Society of America The" exact="American" post="College of Cardiology. Patients Taking ACE-i and ARBs Who"/>
  <result pre="and angiotensin ii receptor blockers with mortality among patients with" exact="hypertension" post="hospitalized with COVID-19. Circ Res. (2020). 10.1161/CIRCRESAHA.120.317134. [Epub ahead"/>
  <result pre="inhibitors and angiotensin receptor blockers on death and severity of" exact="disease" post="in patients with coronavirus disease 2019 (COVID-19): a meta-analysis."/>
  <result pre="on death and severity of disease in patients with coronavirus" exact="disease" post="2019 (COVID-19): a meta-analysis. medRxiv [Preprint]. (2020). 10.1101/2020.04.23.20076661 10.UhalBDAbdul-HafezA."/>
  <result pre="10.UhalBDAbdul-HafezA. Angiotensin II in apoptotic lung injury: potential role in" exact="meconium aspiration syndrome." post="J Perinatol. (2008) 28(Suppl. 3):S108â€&quot;12. 10.1038/jp.2008.14919057599 11.UhalBDLiXPiaseckiCCMolina-MolinaM. Angiotensin signalling"/>
  <result pre="J Perinatol. (2008) 28(Suppl. 3):S108â€&quot;12. 10.1038/jp.2008.14919057599 11.UhalBDLiXPiaseckiCCMolina-MolinaM. Angiotensin signalling in" exact="pulmonary" post="fibrosis. Int J Biochem Cell Biol. (2012) 44:465â€&quot;8. 10.1016/j.biocel.2011.11.01922155301"/>
  <result pre="system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and" exact="kidney diseases." post="Pharmacol Res. (2017) 125:21â€&quot;38. 10.1016/j.phrs.2017.06.00528619367 13.KubaKImaiYRaoSGaoHGuoFGuanBet al.. A crucial"/>
  <result pre="SARS coronavirus-induced lung injury. Nat Med. (2005) 11:875â€&quot;9. 10.1038/nm126716007097 14.YanRZhangYLiYXiaLGuoYZhouQ." exact="Structural" post="basis for the recognition of the SARS-CoV-2 by full-length"/>
  <result pre="ACE2. Science. (2020) 367:1444â€&quot;8. 10.1101/2020.02.19.95694632132184 15.WuKLiWPengGLiF. Crystal structure of NL63" exact="respiratory" post="coronavirus receptor-binding domain complexed with its human receptor. Proc"/>
  <result pre="Virol J. (2010) 4:76â€&quot;84. 10.2174/187435790100401007620700397 17.MathewsonACBishopAYaoYKempFRenJChenHet al.. Interaction of severe" exact="acute" post="respiratory syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin"/>
  <result pre="J. (2010) 4:76â€&quot;84. 10.2174/187435790100401007620700397 17.MathewsonACBishopAYaoYKempFRenJChenHet al.. Interaction of severe acute" exact="respiratory" post="syndrome-coronavirus and NL63 coronavirus spike proteins with angiotensin converting"/>
  <result pre="J Gen Virol. (2008) 89:2741â€&quot;5. 10.1099/vir.0.2008/003962-018931070 18.SimmonsGReevesJDRennekampAJAmbergSMPieferAJBatesP. Characterization of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc"/>
  <result pre="Gen Virol. (2008) 89:2741â€&quot;5. 10.1099/vir.0.2008/003962-018931070 18.SimmonsGReevesJDRennekampAJAmbergSMPieferAJBatesP. Characterization of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl"/>
  <result pre="Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated" exact="viral" post="entry. Proc Natl Acad Sci USA. (2004) 101:4240â€&quot;5. 10.1073/pnas.030644610115010527"/>
  <result pre="10.1111/all.14238. [Epub ahead of print]. 24.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708â€&quot;20."/>
  <result pre="improves oxygenation, while reducing cellular infiltrate and fibrosis in experimental" exact="acute" post="respiratory distress syndrome. Intensive Care Med Exp. (2015) 3:44."/>
  <result pre="oxygenation, while reducing cellular infiltrate and fibrosis in experimental acute" exact="respiratory" post="distress syndrome. Intensive Care Med Exp. (2015) 3:44. 10.1186/s40635-015-0044-326215809"/>
  <result pre="syndrome. Intensive Care Med Exp. (2015) 3:44. 10.1186/s40635-015-0044-326215809 27.MarshallRP. The" exact="pulmonary" post="renin-angiotensin system. Curr Pharm Des. (2003) 9:715â€&quot;22. 10.2174/138161203345543112570789 28.UhalBDDangMDangVLlatosRCanoEAbdul-HafezAet"/>
  <result pre="28.UhalBDDangMDangVLlatosRCanoEAbdul-HafezAet al.. Cell cycle dependence of ACE-2 explains downregulation in" exact="idiopathic pulmonary fibrosis." post="Eur Respir J. (2013) 42:198â€&quot;210. 10.1183/09031936.0001561223100504 29.HammingICooperMEHaagmansBLHooperNMKorstanjeROsterhausADet al.. The"/>
  <result pre="al.. Cell cycle dependence of ACE-2 explains downregulation in idiopathic" exact="pulmonary" post="fibrosis. Eur Respir J. (2013) 42:198â€&quot;210. 10.1183/09031936.0001561223100504 29.HammingICooperMEHaagmansBLHooperNMKorstanjeROsterhausADet al.."/>
  <result pre="al.. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent" exact="cardiomyopathy" post="in ACE2 null mice. Cardiovasc Res. (2007) 75:29â€&quot;39. 10.1016/j.cardiores.2007.04.00717499227"/>
  <result pre="(2007) 75:29â€&quot;39. 10.1016/j.cardiores.2007.04.00717499227 36.MoriJPatelVBRamprasathTAlrobOADesAulniersJScholeyJWet al.. Angiotensin 1-7 mediates renoprotection against" exact="diabetic nephropathy" post="by reducing oxidative stress, inflammation, and lipotoxicity. Am J"/>
  <result pre="75:29â€&quot;39. 10.1016/j.cardiores.2007.04.00717499227 36.MoriJPatelVBRamprasathTAlrobOADesAulniersJScholeyJWet al.. Angiotensin 1-7 mediates renoprotection against diabetic" exact="nephropathy" post="by reducing oxidative stress, inflammation, and lipotoxicity. Am J"/>
  <result pre="by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol" exact="Renal" post="Physiol. (2014) 306:F812â€&quot;21. 10.1152/ajprenal.00655.201324553436 37.ZieglerCGKAllonSJNyquistSKMbanoIMMiaoVNTzouanasCNet al.. SARS-CoV-2 receptor ACE2"/>
  <result pre="SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway" exact="epithelial" post="cells and is detected in specific cell subsets across"/>
  <result pre="Cell. (2020). 10.1016/j.cell.2020.04.035. [Epub ahead of print].32413319 38.BanachSBOrensteinJMFoxLMRandellSHRowleyAHBakerSC. Human airway" exact="epithelial" post="cell culture to identify new respiratory viruses: coronavirus NL63"/>
  <result pre="print].32413319 38.BanachSBOrensteinJMFoxLMRandellSHRowleyAHBakerSC. Human airway epithelial cell culture to identify new" exact="respiratory" post="viruses: coronavirus NL63 as a model. J Virol Methods."/>
  <result pre="(2009) 156:19â€&quot;26. 10.1016/j.jviromet.2008.10.02219027037 39.JiaHPLookDCShiLHickeyMPeweLNetlandJet al.. ACE2 receptor expression and severe" exact="acute" post="respiratory syndrome coronavirus infection depend on differentiation of human"/>
  <result pre="156:19â€&quot;26. 10.1016/j.jviromet.2008.10.02219027037 39.JiaHPLookDCShiLHickeyMPeweLNetlandJet al.. ACE2 receptor expression and severe acute" exact="respiratory" post="syndrome coronavirus infection depend on differentiation of human airway"/>
  <result pre="10.1016/j.jviromet.2008.10.02219027037 39.JiaHPLookDCShiLHickeyMPeweLNetlandJet al.. ACE2 receptor expression and severe acute respiratory" exact="syndrome" post="coronavirus infection depend on differentiation of human airway epithelia."/>
  <result pre="al.. ACE2 receptor expression and severe acute respiratory syndrome coronavirus" exact="infection" post="depend on differentiation of human airway epithelia. J Virol."/>
  <result pre="41.CrackowerMASaraoROuditGYYagilCKozieradzkiIScangaSEet al.. Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="function. Nature. (2002) 417:822â€&quot;8. 10.1038/nature0078612075344 42.GallagherPEFerrarioCMTallantEA. Regulation of ACE2"/>
  <result pre="of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol" exact="Heart" post="Circ Physiol. (2008) 295:H2373â€&quot;9. 10.1152/ajpheart.00426.200818849338 43.ChenYYZhangPZhouXMLiuDZhongJCZhangCJet al.. Relationship between"/>
  <result pre="44.Soro-PaavonenAGordinDForsblomCRosengard-BarlundMWadenJThornLet al.. Circulating ACE2 activity is increased in patients with" exact="type 1" post="diabetes and vascular complications. J Hypertens. (2012) 30:375â€&quot;83. 10.1097/HJH.0b013e32834f04b622179088"/>
  <result pre="Circulating ACE2 activity is increased in patients with type 1" exact="diabetes" post="and vascular complications. J Hypertens. (2012) 30:375â€&quot;83. 10.1097/HJH.0b013e32834f04b622179088 45.GallagherPEFerrarioCMTallantEA."/>
  <result pre="activity is increased in patients with type 1 diabetes and" exact="vascular" post="complications. J Hypertens. (2012) 30:375â€&quot;83. 10.1097/HJH.0b013e32834f04b622179088 45.GallagherPEFerrarioCMTallantEA. MAP kinase/phosphatase"/>
  <result pre="46.ChenTWuDChenHYanWYangDChenGet al.. Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective study. BMJ. (2020) 368:m1091. 10.1136/bmj.m109132217556 47.NgKKVaneJR. Conversion"/>
  <result pre="I to angiotensin II. Nature. (1967) 216:762â€&quot;6. 10.1038/216762a04294626 48.InciardiRMLupiLZacconeGItaliaLRaffoMTomasoniDet al.." exact="Cardiac" post="involvement in a patient with coronavirus disease 2019 (COVID-19)."/>
  <result pre="10.1038/216762a04294626 48.InciardiRMLupiLZacconeGItaliaLRaffoMTomasoniDet al.. Cardiac involvement in a patient with coronavirus" exact="disease" post="2019 (COVID-19). JAMA Cardiol. (2020). 10.1001/jamacardio.2020.1096. [Epub ahead of"/>
 </snippets>
</snippetsTree>
